Akèy › Maladi Crohn › Virginia
Etid klinik pou Maladi Crohn nan Virginia
15 etid pou Maladi Crohn ap chèche patisipan nan sit nan Virginia.
Vil nan Virginia
Tèks ofisyèl etid la (Anglè)
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- University of Virginia Health System ( Site 0291), Charlottesville
Ap rekriteFaz 3
Tout laj · Tout sèks · Mizajou Oct 2, 2026 · NCT06651281A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Richmond VA Medical Center ( Site 5021), Richmond
Ap rekriteFaz 3
Laj 16 a 80 · Tout sèks · Mizajou Oct 2, 2026 · NCT06430801Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Emeritas Research Group /ID# 284388, Lansdowne Town Center
- GI Alliance - Richmond /ID# 284244, Richmond
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Gastroenterology Consultants of Southwest Virginia., Roanoke
Ap rekriteFaz 4
Laj 18 a 80 · Tout sèks · Mizajou Sep 30, 2026 · NCT06581328A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- Gastroenterology Associates of Tidewater, Chesapeake
- Blue Ridge Medical Research, Lynchburg
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07196722Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- VCU Massey Comprehensive Cancer Center, Richmond
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT03816345An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Blue Ridge Medical Research-Site Number: 8400020, Lynchburg
- Clinical Research Partners-Site Number: 8400080, Richmond
Ap rekriteFaz 3
Laj 16 a 80 · Tout sèks · Mizajou Sep 23, 2026 · NCT07184931A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
- Gastroenterology Associates of Central Virginia, Lynchburg
Ap rekriteFaz 2
Laj 18 a 85 · Tout sèks · Mizajou Sep 22, 2026 · NCT06226883A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
- Pediatric Specialists of Virginia, Fairfax
Ap rekriteFaz 3
Laj 2 a 19 · Tout sèks · Mizajou Sep 22, 2026 · NCT04844606A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Carilion Children's Tanglewood Center, Roanoke
Ap rekriteFaz 3
Laj 2 ak plis · Tout sèks · Mizajou May 7, 2026 · NCT05442567Precise Infliximab Exposure and Pharmacodynamic Control
- Children's Specialty Group, Norfolk
Ap rekriteFaz 2/3
Laj 6 a 22 · Tout sèks · Mizajou May 5, 2026 · NCT05660746A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
- Carilion Children's Tanglewood Center, Roanoke
Ap rekriteFaz 3
Laj 2 a 17 · Tout sèks · Mizajou May 5, 2026 · NCT04779320Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
- Richmond VA Medical Center, Richmond
- Gastroenterology Consultants of Southwest Virginia., Roanoke
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Apr 27, 2026 · NCT06456593Ketogenic and Carnivore (Lion) Diets for Inflammatory Bowel Disease and Rheumatoid Arthritis
- Resilient Roots: Functional Medicine, Charlottesville
Ap rekrite
Laj 18 a 64 · Tout sèks · Mizajou Apr 16, 2026 · NCT07524244A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
- Investigational Site Number: 8400027, Richmond
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Mar 27, 2026 · NCT06958536Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.